Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 50Other hematologic neoplasm 22Plasma cell 4Myeloid 4Dermatologic 3Sarcoma 2Other neoplasm 2Genitourinary 2Thoracic 1Other solid neoplasm 1Gynecologic 1Classical hematology 1Breast 1

Conditions

Ovarian Neoplasms 2573Uterine Cervical Neoplasms 1693Endometrial Neoplasms 1012Fallopian Tube Neoplasms 730Carcinoma, Ovarian Epithelial 681Breast Neoplasms 676Neoplasms 436Carcinoma, Non-Small-Cell Lung 379Colorectal Neoplasms 372Stomach Neoplasms 302Pancreatic Neoplasms 302Uterine Cervical Dysplasia 273Prostatic Neoplasms 262Lung Neoplasms 250Melanoma 247Neoplasm Metastasis 216Peritoneal Neoplasms 197Carcinoma, Renal Cell 193Sarcoma 190Head and Neck Neoplasms 189Urinary Bladder Neoplasms 187Esophageal Neoplasms 187Recurrence 185Triple Negative Breast Neoplasms 181Uterine Neoplasms 176Vulvar Neoplasms 173Squamous Cell Carcinoma of Head and Neck 168Colonic Neoplasms 162Papillomavirus Infections 153Small Cell Lung Carcinoma 128

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphatic Diseases × Gynecologic × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡